MET and glioblastoma: In response to the anti-angiogenic therapy in GBM, VEGFR2 was found to phosphorylate MET leading to invasion and therapeutic resistance via activation of the signal transducer and activator of transcription 3 (STAT3; Lu et al., 2012; Jahangiri et al., 2013).